Enlivex Ltd.

Enlivex Ltd. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy, for age-related symptomatic knee osteoarthritis (OA) in patients aged 64 and older. This designation is based on positive clinical evidence from the completed Phase I/IIa trial and is expected to expedite Allocetra™'s development and approval process, offering benefits like intensive FDA engagement and potential for accelerated approval. The company has initiated a Phase IIb clinical trial and expects top-line data by the end of Q2 2027, with the FDA requesting a Type B meeting to discuss the development program.

Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026. This action will combine every 15 ordinary shares into one, reducing the number of authorized shares from 2,375,000,000 to 158,333,334 and issued/outstanding shares from 252,480,222 to approximately 16,832,015. The par value will increase from NIS 0.40 to NIS 6.00, and fractional shares will be rounded up.

Enlivex Ltd. announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026. This listing aims to expand market access and secondary liquidity for the token, as Gate is one of the world's largest exchanges by spot trading volume, serving over 54 million users globally. As of June 21, 2026, Enlivex held RAIN tokens valued at approximately $1.14 billion, representing a treasury NAV per Share of $4.67.

Enlivex announced its primary treasury asset, the RAIN token, is now listed on the Gate cryptocurrency exchange, effective June 24, 2026. This listing is expected to significantly increase the token's accessibility, global reach, and liquidity, as Gate is a top-tier exchange with over 54 million users and the second-largest 24-hour spot trading volume globally. Enlivex's digital asset treasury strategy involves acquiring RAIN tokens, with current holdings valued at approximately $1.14 billion, representing a treasury NAV per share of $4.67.

Enlivex Ltd. announced that it issued a press release on June 22, 2026. The press release provides an update regarding the company's holdings of RAIN tokens. This information was furnished as Exhibit 99.1 to the 6-K filing.

Enlivex Ltd. provided an update on its RAIN token holdings, reporting approximately 79.57 billion RAIN tokens valued at $1.14 billion as of June 20, 2026. This resulted in a Treasury NAV per Share of $4.67. The company emphasizes its dual strategy of developing longevity therapeutics and operating a prediction markets treasury.

Enlivex Ltd. provided an update on its RAIN token holdings, which were valued at approximately $1.16 billion as of May 27, 2026, comprising 79,568,550,005 tokens. Separately, the Rain Foundation, which oversees the Rain protocol, announced the appointment of five industry leaders to its advisory board. The Rain Foundation also committed $100 million in liquidity to the protocol, positioning it as the third-largest prediction market protocol globally by Total Value Locked (TVL).

Enlivex Ltd. commented on the Rain Foundation's announcement of a $100 million liquidity commitment to its prediction markets protocol. This increased liquidity positions Rain as the third-largest prediction market protocol globally by Total Value Locked (TVL), alongside Polymarket and Kalshi. Enlivex's Executive Chairman, Shai Novik, stated that this is a major step for Rain and a meaningful validation of Enlivex's treasury strategy. As of May 26, 2026, Enlivex's RAIN token holdings were valued at approximately $919 million, and it holds an option to acquire additional RAIN tokens with an intrinsic value of $2.23 billion.

Enlivex Ltd. announced the dosing of the first patient at a United States clinical site in its global Phase 2b clinical trial of Allocetra for moderate-to-severe age-related symptomatic primary knee osteoarthritis. This milestone follows FDA IND clearance in March 2026 and Danish Medicines Agency approval in April 2026. The trial aims to evaluate the efficacy and safety of Allocetra, with key endpoints including changes in pain and physical function at three and six months, addressing a significant unmet medical need.

Enlivex Ltd. announced it received a notice from Nasdaq Stock Market LLC for not meeting the $1.00 minimum bid price requirement over the past 30 consecutive business days. The company has an initial 180-calendar-day period, until November 9, 2026, to regain compliance by having its ordinary shares trade at or above $1.00 for at least 10 consecutive business days. Failure to comply could lead to delisting, though an additional 180-day period may be granted under certain conditions. The notice does not immediately affect the company's Nasdaq listing or operations.